Released Aug 7, 2020, before the open
10-Q filed Aug 7, 2020, 38 days after period end · 0001493152-20-014994
Q2 2020 · 10-Q
Revenue$754.00K$754.00K −85.6% vs Q2 2019−68.5% vs Q1 2020
Net Income-$2.03M-$2.03M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.12-$0.12 N/M vs Q2 2019N/M vs Q1 2020
Operating Income-$2,019,201N/M
Operating Cash Flowderived-$2,183,529N/M
Free Cash Flowderived-$2,205,249N/M
Margins · derived
Operating margin-267.8%−267.8 pt vs Q2 2019
Net margin-269.7%−268.0 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $754.00K | $5.23M | $5.65M | $5.55M |
| Net Income | -$2.03M | -$90.00K | -$124.00K | -$164.00K |
| EPS Diluted | -$0.12 | -$0.03 | -$0.05 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR